Who is sponsoring NCT05404022?

NCT05404022 is sponsored by University of Hull.

What drugs are being tested in NCT05404022?

Interventions in NCT05404022: Tailored nutrition and physical activity programme.

What condition does NCT05404022 study?

NCT05404022 studies Lung Neoplasm Malignant, Mesothelioma; Lung.

Is NCT05404022 still recruiting?

NCT05404022 is currently completed. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT05404022: CanBenefitII

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years

Completed NA Last updated 13 September 2023

What this trial tests

NA trial testing Tailored nutrition and physical activity programme in Lung Neoplasm Malignant in 11 participants. Completed in 1 September 2023.

Timeline

20 June 2022

Primary endpoint
1 September 2023

1 September 2023

Quick facts

Lead sponsor	University of Hull
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	20 June 2022
Primary completion	1 September 2023
Estimated completion	1 September 2023
Sites	2 locations across United Kingdom

Drugs / interventions tested

Tailored nutrition and physical activity programme

Conditions studied

Lung Neoplasm Malignant — all drugs for Lung Neoplasm Malignant →
Mesothelioma; Lung — all drugs for Mesothelioma; Lung →

Sponsor

University of Hull

Who can join

65 and older, any sex, with Lung Neoplasm Malignant or Mesothelioma; Lung. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

People with cancer affecting the lungs tend to be older and frailer compared to people with other cancers. As a result, they may have poorer quality of life and are less able to tolerate treatments for their cancer, such as chemotherapy. Research to date show that nutrition and physical activity support helps people with cancer, but not many older people are included in these studies. The investigators want to develop and test a nutrition and activity programme for older people with lung cancer that can be tailored to each patient to help them have the best possible quality of life from the moment they start a new line of cancer treatment. The research team has conducted the development work to find which nutrition and activity programmes are best for this patient group and how best to deliver the programme by looking at prior studies and talking to patients and carers as well as health care providers. The next step is to test the developed programme in a small pilot study, to i) see if it is possible and acceptable (to patients, families, and staff) to deliver and ii) see if it helps patients have and cope with anti-cancer treatments and improve patient quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combined Nutritional and Exercise Interventions for Cachexia in Chronic Diseases: A Systematic Review and Meta-analysis Limited to Cancer Cachexia.
Okamura M, Shirado K, Shirai N, Yagi T, et al · · 2026 · PMID 41884877 · DOI 10.2490/prm.20260012

Verify or expand the search:

Other recruiting trials for Lung Neoplasm Malignant

Currently open trials in the same condition.

NCT07286149 — A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) · Phase 1, PHASE2 · recruiting
NCT07071103 — Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors · Phase 2 · recruiting
NCT06788912 — Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAK · Phase 2 · recruiting
NCT06440616 — Benefit of Spectral Information in Patients Suspected for Lung Cancer · NA · recruiting
NCT06079970 — Confocal Laser Endomicroscopy VERification · NA · recruiting

Other University of Hull trials

Trials by the same sponsor.

NCT05646199 — Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS) · Phase 2, PHASE3 · not yet recruiting
NCT06276686 — Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer · EARLY_PHASE1 · recruiting
NCT07299682 — Facilitating Effective Eating With DoddleBags: A Single-Arm Acceptability Study Of DoddleBags to Assess Impact on Self F · NA · recruiting
NCT07376694 — Improving Uptake of Bowel Cancer Screening Among South Asian Adults in Bradford · NA · active not recruiting
NCT06595316 — Exercise for Ameliorating Chemotherapy Cardiotoxicity · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05404022 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Hull
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05404022.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing